Identified prognostic factors favouring the occurrence of neutropenia during treatment with FTD/TPI were time since diagnosis of the first metastasis of ≥18 months, baseline haemoglobin ≥110 g/l, NLR < 3, baseline AST grade 0, baseline albumin ≥35 g/l, previous lines of treatment > 2, and baseline white blood cell count < 10 × 109/l (Supplementary Table 2). The gene discussed is ALB; the disease is neutropenia.